KPCM
JUNO

Kings Point Capital Management’s Juno Therapeutics, Inc. JUNO Stock Holding History

Kings Point Capital Management’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-200
Closed -$11K – 394
2015
Q2 		$11K Hold
200
– – ﹤0.01% 349
2015
Q1 		$12K Buy
+200
New +$9.71K ﹤0.01% 347

Other funds holding JUNO

CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GAMA
Graticule Asia Macro Advisors New York $649M AUM

Kings Point Capital Management's JUNO Position: Q3 2015 in Review

Kings Point Capital Management sold out of Juno Therapeutics, Inc. (JUNO) in Q3 2015, closing a stake of 200 shares — an estimated $11K sold.

Kings Point Capital Management first reported a position in JUNO in Q1 2015 and held it in 2 quarters. The position peaked at $12K in Q1 2015. 132 funds tracked by Wall St. Rank hold JUNO as of Q3 2015.

  • Kings Point Capital Management reported no remaining Juno Therapeutics, Inc. position as of Q3 2015 after selling out during the quarter.
  • Kings Point Capital Management sold 200 Juno Therapeutics, Inc. shares in Q3 2015, an estimated $11K.
  • Kings Point Capital Management first reported a position in Juno Therapeutics, Inc. in Q1 2015 and held it in 2 quarters.
  • Kings Point Capital Management's Juno Therapeutics, Inc. position peaked at $12K in Q1 2015.
  • 132 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q3 2015.

Based on Kings Point Capital Management's 13F filing for Q3 2015, filed 12 Nov 2015.